NewGenIvf Group Limited (NASDAQ:NIVF) Short Interest Update

NewGenIvf Group Limited (NASDAQ:NIVF) was the recipient of a large decrease in short interest in July. As of July 15th, there was short interest totaling 67,374 shares, a decrease of 89.7% from the June 30th total of 654,534 shares. Based on an average daily trading volume, of 485,212 shares, the days-to-cover ratio is presently 0.1 days. Approximately 2.9% of the company’s shares are short sold.

Insider Transactions at NewGenIvf Group

In other news, major shareholder Financial Lp Hrt acquired 45,847 shares of the firm’s stock in a transaction on Friday, May 22nd. The shares were purchased at an average cost of $2.97 per share, for a total transaction of $136,165.59. Following the transaction, the insider owned 37,295 shares of the company’s stock, valued at approximately $110,766.15. This represents a -536.10% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 31.80% of the company’s stock.

NewGenIvf Group Price Performance

Shares of NIVF traded down $0.12 on Friday, reaching $1.10. 176,396 shares of the company’s stock were exchanged, compared to its average volume of 934,198. The business has a 50 day moving average price of $1.94 and a two-hundred day moving average price of $7.11. NewGenIvf Group has a 12 month low of $1.10 and a 12 month high of $568.53. The company has a current ratio of 3.12, a quick ratio of 2.98 and a debt-to-equity ratio of 0.16.

NewGenIvf Group (NASDAQ:NIVF) last released its earnings results on Tuesday, March 31st. The company reported ($861.72) EPS for the quarter. The business had revenue of $1.42 million for the quarter. Research analysts expect that NewGenIvf Group will post 14.22 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on NIVF shares. Wall Street Zen upgraded NewGenIvf Group to a “hold” rating in a research report on Saturday, July 4th. Weiss Ratings reiterated a “sell (d)” rating on shares of NewGenIvf Group in a report on Monday, April 27th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.

NewGenIvf Group Company Profile

NewGenIVF Group Inc, trading on NASDAQ under the symbol NIVF, is an integrated provider of reproductive medicine services in the People’s Republic of China. The company operates a network of fertility clinics across major Chinese cities, delivering comprehensive infertility diagnosis and treatment to patients and couples. Its facilities are equipped with modern laboratories and surgical suites designed for assisted reproductive procedures.

NewGenIVF’s service offerings encompass a wide range of assisted reproductive technologies (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and fertility preservation through ovarian tissue and gamete cryopreservation.